Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.
The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed exercised employee stock options and sold shares in a planned transaction. She exercised options for 10,000 shares of common stock at $15.46 per share and then sold 10,000 shares at $30.00 per share on the same day. After these transactions, she directly holds 105,211 shares of Travere Therapeutics common stock. The filing notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements, and that the underlying stock option grant from January 31, 2020 is fully vested and exercisable.
TVTX filed a Form 144 disclosing the intended sale of 60,000 shares of Common Stock on 04/01/2026. The filing lists the sale method as cash and records several prior dispositions in the past three months: 8,135; 51,865; 100,087; and 60,000 shares on specified dates.
Elizabeth Reed reported the proposed sale of 10,000 shares of Common Stock under Form 144, linked to a stock option exercise dated 04/01/2026. The filing lists multiple earlier dispositions in 2026: 10,000 shares on 03/16/2026 for $280,861.00, 10,000 on 02/17/2026 for $278,317.00, and other smaller sales in February and January.
Travere Therapeutics Inc ownership filing shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries and divisions to report holdings separately in reliance on SEC Release No. 34-39538.
Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026. The filing also lists prior dispositions by Ms. Reed in the past three months: $278,317.00 for 10,000 shares on 02/17/2026, $96,360.09 for 2,994 shares on 02/04/2026, $230,463.88 for 7,175 shares on 02/03/2026, and $273,420.00 for 10,000 shares on 01/20/2026.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised stock options for 60,000 shares on February 20, 2026, converting an employee stock option into common stock at an exercise price of $15.4600 per share. He then sold 60,000 common shares in an open-market transaction at a weighted average price of $30.0961, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, his directly held common stock position was 432,886 shares.
TVTX filing: a Form 144 notice reports proposed sales of common shares by an affiliate and by Eric M. Dube. The filing lists an affiliate sale of 60,000 shares on 02/20/2026 (option originally granted 01/31/2020), and three recent sales by Eric M. Dube: 8,135, 51,865, and 100,087 shares on 01/23/2026, 01/27/2026, and 02/03/2026, respectively, with cash consideration shown.
Travere Therapeutics files its annual report describing a rare‑disease focused biopharma business built around FILSPARI and a growing pipeline. The company now has full FDA approval for FILSPARI to slow kidney function decline in adults with IgA nephropathy and is pursuing an additional indication in focal segmental glomerulosclerosis, with a supplemental application under FDA review and an April 13, 2026 PDUFA date.
Travere is also advancing pegtibatinase in a pivotal Phase 3 trial for classical homocystinuria after resolving manufacturing scale‑up issues and restarting enrollment in 2026. Existing revenue comes from rare kidney and metabolic products, including Thiola/Thiola EC, though these face generic competition. Globally, Travere relies on partners CSL Vifor and Chugai for FILSPARI commercialization outside the United States and highlights extensive patent and orphan‑drug exclusivity intended to protect key assets.